Specifically, a one-point increase in the IGF-1 Z-score is associated with a 29.85% decrease in anxiety symptoms (GAD-7), a 16.30% reduction in depression severity (PHQ-9), and a 39.23% decrease in post-TBI symptom severity (RPQ-13). Here, IGF1 is linked to depressive symptom measurement.